Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

Formononetin inhibits USP5. 2 / 2

| 2

➶

reach

"Small molecules inhibitor WP1130 XREF_BIBR and Chinese medicine Formononetin XREF_BIBR were reported to inhibit USP5, which further indicated that targeting USP5 might be an effective strategy in pancreatic cancer treatment."

33123271

➶

reach

"To investigate the influence of Formononetin on inhibiting USP5, ChIP assay was conducted in cells treated with Formononetin at different concentrations."

30809294

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...